WuXi XDC Cayman Inc.

Equities

2268

KYG9808A1058

Pharmaceuticals

End-of-day quote Hong Kong S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
19.06 USD +0.63% Intraday chart for WuXi XDC Cayman Inc. -17.31% -40.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
WuXi XDC Cayman’s Profit Up 82% in 2023 MT
WuXi XDC Cayman Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
WuXi Shares Fall as Washington Lobbying Group Cuts Ties DJ
WuXi XDC Cayman’s Shares Close 10% Lower Amid Fear of Potential U.S. Sanctions MT
WuXi Companies' Shares Fall Amid Renewed U.S. Sanction Concerns DJ
WuXi Companies' Shares Rise on Receding Worries About Potential U.S. Sanctions DJ
WuXi Shares Hit by U.S. Committee Seeking Inquiry, Blacklisting DJ
US lawmakers call for sanctions on China's WuXi AppTec biotech firm RE
WuXi Companies' Shares Slide Amid Concerns Over Proposed U.S. Bill DJ
WuXi XDC Forecasts 80% Rise in 2023 Profit; Shares Jump 9% MT
WuXi XDC Cayman Inc. Provides Earnings Guidance for the Year Ended December 31, 2023 CI
Wuxi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development CI
MGI Tech Responds to US BIOSECURE Act MT
Wuxi Biologics Clarifies CEO Background Following US Draft Bill MT
WuXi AppTec Shares Continue Slide After Company Calls U.S. Draft Bill Findings Inaccurate DJ
WuXi AppTec Says Findings of U.S. Draft Bill Against Company Aren't Accurate DJ
WuXi Company Shares Tumble on U.S. Bill Aimed at Chinese Biotech -- Update DJ
WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates CI
Wuxix XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development CI
WuXi XDC Says Confident of Meeting Growth Target MT
Alibaba's Scrapped Spin-Off Plan Drags Down Hong Kong Stocks; WuXi XDC Cayman Gains 36% at Debut MT
WuXi Biologics Arm WuXi XDC Lists on HKEX MT
Wuxi XDC Cayman Shares Surge on Hong Kong Debut -- Update DJ
WuXi XDC Cayman Inc. has completed an IPO in the amount of HKD 3.675988 billion. CI
WuXi XDC Cayman Raises HK$3.48 Billion from Hong Kong IPO, Prices at Top of Range MT
Chart WuXi XDC Cayman Inc.
More charts
WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
17.62 CNY
Average target price
28.8 CNY
Spread / Average Target
+63.39%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2268 Stock
  4. News WuXi XDC Cayman Inc.
  5. WuXi XDC Forecasts 80% Rise in 2023 Profit; Shares Jump 9%
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW